1. Home
  2. BNGO vs IMNN Comparison

BNGO vs IMNN Comparison

Compare BNGO & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bionano Genomics Inc.

BNGO

Bionano Genomics Inc.

HOLD

Current Price

$1.12

Market Cap

11.6M

Sector

Industrials

ML Signal

HOLD

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$3.38

Market Cap

12.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNGO
IMNN
Founded
2003
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.6M
12.5M
IPO Year
2018
2000

Fundamental Metrics

Financial Performance
Metric
BNGO
IMNN
Price
$1.12
$3.38
Analyst Decision
Strong Buy
Buy
Analyst Count
3
2
Target Price
$6.33
$182.61
AVG Volume (30 Days)
135.4K
26.2K
Earning Date
03-30-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.00
EPS
N/A
N/A
Revenue
$12,000,735.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$24.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
26.26
N/A
52 Week Low
$1.06
$0.37
52 Week High
$5.50
$9.32

Technical Indicators

Market Signals
Indicator
BNGO
IMNN
Relative Strength Index (RSI) 34.85 59.53
Support Level $1.06 $3.53
Resistance Level $1.18 $3.62
Average True Range (ATR) 0.05 0.21
MACD 0.01 0.05
Stochastic Oscillator 30.53 92.98

Price Performance

Historical Comparison
BNGO
IMNN

About BNGO Bionano Genomics Inc.

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Share on Social Networks: